Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Objective: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB).

Materials and Methods: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated.

Results: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively.

Conclusion: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.

Original languageEnglish
Pages (from-to)125-132
Number of pages8
JournalKorean Journal of Radiology
Volume16
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Ethiodized Oil
Porifera
Gelatin
Microspheres
Doxorubicin
Hepatocellular Carcinoma
Therapeutics
Pharmaceutical Preparations
Safety
Neoplasms

All Science Journal Classification (ASJC) codes

  • Radiology Nuclear Medicine and imaging

Cite this

@article{1bcd26db37c04d3d89a4290e7cede10f,
title = "Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma",
abstract = "Objective: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB).Materials and Methods: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5{\%}) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9{\%}) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5{\%}) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated.Results: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1{\%} vs. 6.3{\%} or 2.4{\%}). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0{\%} vs. 57.8{\%} or 68.3{\%}). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7{\%}, 34.1{\%}, and 5.7{\%}, respectively.Conclusion: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.",
author = "Yi-Sheng Liu and Ming-Ching Ou and Yi-Shan Tsai and Xi-Zhang Lin and Chien-Kuo Wang and Hong-Ming Tsai and Ming-Tsung Chuang",
year = "2015",
month = "1",
day = "1",
doi = "10.3348/kjr.2015.16.1.125",
language = "English",
volume = "16",
pages = "125--132",
journal = "Korean Journal of Radiology",
issn = "1229-6929",
publisher = "Korean Radiological Society",
number = "1",

}

TY - JOUR

T1 - Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma

AU - Liu, Yi-Sheng

AU - Ou, Ming-Ching

AU - Tsai, Yi-Shan

AU - Lin, Xi-Zhang

AU - Wang, Chien-Kuo

AU - Tsai, Hong-Ming

AU - Chuang, Ming-Tsung

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Objective: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB).Materials and Methods: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated.Results: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively.Conclusion: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.

AB - Objective: To retrospectively compare treatment of hepatocellular carcinoma (HCC) with transarterial chemoembolization (TACE) using gelatin sponges or microspheres plus lipiodol-doxorubicin vs. doxorubicin-loaded drug-eluting beads (DEB).Materials and Methods: A total of 158 patients with HCC received TACE from November 2010 to November 2011 were enrolled in this study, including 64 (40.5%) received TACE with lipiodol-doxorubicin and gelatin sponges (group A), 41 (25.9%) received TACE with lipiodol-doxorubicin and microspheres (group B), and 53 (33.5%) received TACE with doxorubicin-loaded DEB (group C). Tumor response and adverse events (AEs) were evaluated.Results: No significant difference was found at baseline among the three groups. The doxorubicin dosage in group C was significantly (p < 0.001) higher compared to the dose used in groups A or B (median, 50 mg vs. 31 mg or 25 mg). Significantly (p < 0.001) more patients in group C achieved complete response compared to those in groups A or B (32.1% vs. 6.3% or 2.4%). Significantly (p < 0.001) less patients in group C had progressive disease compared to those in groups A or B (34.0% vs. 57.8% or 68.3%). Minor AEs were more common in groups A and B compared to group C, with rates of 54.7%, 34.1%, and 5.7%, respectively.Conclusion: In patients with HCC, TACE with DEB offers better safety and efficacy profiles compared to either TACE with gelatin sponges or TACE with microspheres.

UR - http://www.scopus.com/inward/record.url?scp=84921780642&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921780642&partnerID=8YFLogxK

U2 - 10.3348/kjr.2015.16.1.125

DO - 10.3348/kjr.2015.16.1.125

M3 - Article

C2 - 25598680

AN - SCOPUS:84921780642

VL - 16

SP - 125

EP - 132

JO - Korean Journal of Radiology

JF - Korean Journal of Radiology

SN - 1229-6929

IS - 1

ER -